Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Aflibercept is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Aflibercept is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Efdamrofusp Alfa (IBI302) appears in 1 tracked Biotech story from March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Efdamrofusp Alfa (IBI302). Shared-story counts are live from our verified record — not editorial picks.
NDA Submission
Anticipated filing of the New Drug Application with the NMPA.
Primary Endpoint Met
Innovent announces positive top-line results from the Phase 3 STAR study.
STAR Study Initiation
Commencement of the Phase 3 registration trial across multiple sites in China.
Phase 2 Completion
Phase 2 data showed promising safety and efficacy in nAMD patients.
Innovent Biologics' IBI302 (efdamrofusp alfa) successfully met its primary endpoint in the Phase 3 STAR registration trial for neovascular age-related macular degeneration. As the first domestically developed extended-interval treatment in China, it represents a significant shift toward reducing the injection burden for millions of patients.
Source: prnewswire.com · manilatimes.net
Efdamrofusp Alfa (IBI302) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
